Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Astrazeneca Plc Ord
(OP:
AZNCF
)
127.74
+1.18 (+0.94%)
Streaming Delayed Price
Updated: 2:20 PM EST, Nov 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Astrazeneca Plc Ord
< Previous
1
2
3
4
5
6
7
8
9
Next >
AstraZeneca Abandons Blood Cancer, Cardiovascular Programs Amid Portfolio Prioritization
July 28, 2023
Earlier today, AstraZeneca plc (NASDAQ: AZN)
Via
Benzinga
AstraZeneca Q2 Earnings Beat Consensus Despite Zero COVID-19 Vaccine Sales, Stock Shoots Up
July 28, 2023
AstraZeneca Plc's (NASDAQ: AZN) unit Alexion has
Via
Benzinga
AstraZeneca-Sanofi's Respiratory Syncytial Virus Treatment Scores FDA Approval To Prevent Infection In Infants
July 18, 2023
The FDA approved AstraZeneca Plc (NASDAQ:
Via
Benzinga
AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
July 03, 2023
AstraZeneca Plc (NASDAQ: AZN) reported high-level results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) in patients with locally advanced or metastatic non-small cell lung...
Via
Benzinga
AstraZeneca's Imfinzi/Imjudo Combo Shows Sustained Overall Survival Benefit At Four Years In Liver Cancer
June 29, 2023
AstraZeneca Plc (NASDAQ: AZN) released updated results from the HIMALAYA Phase 3 trial evaluating Imfinzi (durvalumab) plus Imjudo (tremelimumab-actl) in unresectable hepatocellular carcinoma (HCC)...
Via
Benzinga
AstraZeneca Seeks Expanded Use For Soliris As First Targeted Therapy For Pediatric Patients With Autoimmune Neuromuscular Disease
June 26, 2023
The European Union has reco
Via
Benzinga
Why Are Pieris Pharmaceuticals Shares Tanking Today
June 21, 2023
Pieris Pharmaceuticals Inc (NASDAQ: PIRS) announced that partner AstraZeneca plc (NASDAQ: AZN) decided to discontinue and cease dosing in the ongoing clinical studies of elarekibep, an inhaled IL-4...
Via
Benzinga
AstraZeneca Mulls China Business Unit Spin-Off Amid Geopolitical Tensions
June 20, 2023
European drugmaker AstraZeneca plc (NASDAQ: AZN) is reportedly drafting a plan to spin off its China business, and listing a separate unit in Hong Kong is considered an option amid mounting...
Via
Benzinga
AstraZeneca's Add On Treatment With Standard Care Improves Hemoglobin Levels In Rare Blood Disorder
June 09, 2023
AstraZeneca Plc (NASDAQ: AZN)
Via
Benzinga
AstraZeneca Inks Over $2B Agreement For Cell Therapies Targeting Diabetes
June 09, 2023
AstraZeneca plc (NASDAQ: AZN) has entered into a
Via
Benzinga
Unanimous Support for AstraZeneca and Sanofi's Nirsevimab: Next Generation RSV Treatment on the Horizon
June 09, 2023
The FDA's Antimicrobial Drugs Advisory Committee has voted unanimously 21 to 0 that AstraZeneca plc (NASDAQ: AZN) and Sanofi SA's (NASDAQ: SNY) nirsevimab has a favorable benefit-risk profile t
Via
Benzinga
AstraZeneca's Tagrisso Significantly Enhances Survival in Certain Post Surgery Non-Small Cell Lung Cancer Patients
June 05, 2023
Via
Benzinga
AstraZeneca/Merck's Cancer Drug Combo Shows Positive Results In Endometrial Cancer
May 26, 2023
Via
Benzinga
AstraZeneca's China Executive Seeks Loyalty to "Love the Communist Party" In China
May 19, 2023
During an event held in the city of Wuxi to commemorate its 30th year in China, AstraZeneca Plc's (NASDAQ: AZN) China president, Wang Lei, said the company will seek to be a patriotic company in China...
Via
Benzinga
One More Quits US Pharma Lobby Group: AstraZeneca Follows Teva, AbbVie Footsteps
May 17, 2023
AstraZeneca Plc (NASDAQ: AZN) has decided to leave a U.S. drug lobby group, the Pharmaceutical Research and Manufacturers of America (PhRMA), making it the third company to leave the group in the last...
Via
Benzinga
AstraZeneca' Tagrisso/Chemo Combo Therapy Delays Treatment Resistance, Disease Progression In Certain Type Of Advanced Lung Cancer
May 17, 2023
AstraZeneca Plc (NASDAQ: AZN) has reported topline data
Via
Benzinga
Sanofi, AstraZeneca Release Real-World Data For Respiratory Syncytial Virus Antibody
May 12, 2023
The race to tap the respiratory syncytial virus (RSV) this season intensifies as Sanofi SA (NASDAQ: SNY) and AstraZeneca Plc (NASDAQ: AZN) have
Via
Benzinga
FDA Advisory Committee Votes Favoring Restricted Use Of AstraZeneca/Merck's Prostate Cancer Drug
May 01, 2023
Via
Benzinga
FDA Casts Doubt on Merck/AstraZeneca's Cancer Drug for Prostate Cancer Ahead of Adcomm Meeting
April 27, 2023
The FDA's Oncologic Drugs Advisory Committee will be meeting tomorrow, Friday, 28 April, to discuss the supplemental new drug application (sNDA) for Lynparza (olaparib) in combination with abiraterone...
Via
Benzinga
AstraZeneca's COVID-19 Vaccine Loses Shine, Cancer Drug Imfinzi & Emerging Markets Stabilize Q1 Revenues
April 27, 2023
AstraZeneca Plc (NASDAQ: AZN) has reported Q1 FY23 core EPS of $1.92, up 1% Y/Y (+6% on constant currency), better than the consensus of $1.07. The company clocked Q1 sales of $10.88 billion, -4% (flat...
Via
Benzinga
AstraZeneca, Ionis Unveil Complete Phase 3 Data For ATTR Candidate, Says Drug Halts Disease Progression
April 24, 2023
Via
Benzinga
Why AstraZeneca Shares Are Trading Higher Today?
April 18, 2023
AstraZeneca plc's (NASDAQ: AZN) vaccine head highlighted the confidence that the company's new COVID-19 antibody treatment could protect immunocompromised patients against all known virus variants.
Via
Benzinga
Canadian Cancer Diagnostic Company BioMark Working On Early Lung Detection Assay
April 10, 2023
Via
Benzinga
AstraZeneca' Cancer Drug Combo Meets Goal In Late-Stage Ovarian Cancer Study
April 05, 2023
Via
Benzinga
Pieris Pharma Pushes Elarekibep Data Readout, Investors React Negatively
March 29, 2023
Via
Benzinga
AstraZeneca Axes Pneumonia Drug Pact With Aridis
March 29, 2023
AstraZeneca plc (NASDAQ: AZN) scrapped its license agreement with Aridis Pharmaceuticals Inc (NASDAQ: ARDS).
Via
Benzinga
AstraZeneca-Ionis Partnered Rare Disease Drug Data Shows Sustained Benefit; Drug Under FDA Review
March 27, 2023
Via
Benzinga
AstraZenceca's Tagrisso Shows Survival Benefit In Early-Stage Lung Cancer Settings
March 09, 2023
Via
Benzinga
AstraZeneca's Immunotherapy Imfinzi Shows Improvement In Survival Chances In Lung Cancer Patients
March 09, 2023
Via
Benzinga
AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting
March 06, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.